Privia Health Group, Inc. (PRVA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial metrics, optimistic guidance, and strategic acquisitions, like the Evolent ACO, likely to enhance future profitability. The company’s strategy to deploy capital for growth, coupled with raised guidance, indicates positive market sentiment. Despite some management evasiveness on specifics, the overall tone is confident, suggesting a stock price increase. Given the market cap of $2 billion, the reaction is expected to be moderately positive.
Key Financial Performance
Provider Growth Added 591 providers, a 12.3% increase year-over-year. This growth was attributed to strong new provider signings and implementations across all markets.
Value-Based Attributed Lives Ended the year with 1.54 million value-based attributed lives, up 22.7% year-over-year. Growth driven by implemented provider growth and strong value-based performance.
Practice Collections Increased 16.9% in 2025 to reach $3.47 billion. Growth attributed to implemented provider growth and strong value-based performance.
Adjusted EBITDA Increased 38.8% to $125.5 million in 2025. EBITDA margin as a percentage of care margin expanded 480 basis points to 27.2%. Growth driven by strong operating leverage and G&A expense management.
Cash Balance Ended the year with $480 million, only $11 million below the previous year. This was due to strong cash flow generation, converting 130% of EBITDA to free cash flow.
Attributed Lives Total attributed lives increased 23% year-over-year, driven by new provider growth, the addition of Evolent ACO, and entry into Arizona. Commercial attributed lives increased 16%, CMS Medicare programs up 52%, Medicare Advantage up 15%, and Medicaid up 23%.
Q4 Practice Collections Increased 9.6% year-over-year to $868.7 million. Growth driven by implemented provider growth, solid value-based performance, and ambulatory utilization trends.
Q4 Adjusted EBITDA Increased 26.4% year-over-year to $31.5 million, representing 27% of Care Margin. Margin improvement of 390 basis points year-over-year due to significant operating leverage.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New provider signings: Added 591 providers, a 12.3% increase year-over-year.
Value-based attributed lives: Increased to 1.54 million, up 22.7% year-over-year.
Practice collections: Increased 16.9% in 2025.
Market expansion: Entered Arizona in April with anchor partner IMS, implemented on Privia platform by end of Q3.
Acquisition: Acquired Evolent Health's ACO business, adding over 120,000 value-based attributed lives across existing and new states.
National footprint: Expanded to 24 states and the District of Columbia.
Operational leverage: Adjusted EBITDA increased 38.8% to $125.5 million, with EBITDA margin expanding 480 basis points to 27.2%.
Cash flow generation: Converted 130% of EBITDA to free cash flow, ending the year with $480 million in cash.
Provider retention: Maintained high gross provider retention of 98%.
Value-based care focus: Demonstrated ability to build scale and manage risk without depending on any one contract, with clinical and operational enhancements.
Financial guidance: Guided to 2026 adjusted EBITDA growth of 19.5% and 80% conversion of EBITDA to free cash flow.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Environment: The company operates in a challenging healthcare regulatory environment, which could pose risks to its operations and financial performance.
Dependence on Value-Based Care: While the company has demonstrated strong performance in value-based care, there is a risk associated with managing and scaling this model effectively without over-reliance on specific contracts.
Economic and Market Conditions: The company acknowledges operating in a difficult healthcare services environment, which could impact its financial and operational performance.
Capital Deployment Risks: The company plans to remain disciplined in capital deployment for business development, but there is a risk of misallocation or underperformance of investments.
Cash Flow Conversion: The company expects to convert 80% of EBITDA to free cash flow in 2026, but any deviation from this target could impact financial flexibility.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
EBITDA Growth: Privia Health expects to drive EBITDA growth of approximately 20% at the midpoint of its 2026 guidance.
Cash Position: The company anticipates ending 2026 with approximately $600 million in cash, assuming no new business development.
Implemented Providers: Implemented providers are expected to increase 10.6% year-over-year to reach 5,950 by year-end 2026.
Attributed Lives: Attributed lives are expected to be approximately 1.58 million by the end of 2026.
Practice Collections: Practice collections are projected to grow 6.6% at the midpoint of 2026 guidance.
Care Margin: Care margin is expected to grow 13% at the midpoint of 2026 guidance.
Free Cash Flow Conversion: 80% of full-year 2026 adjusted EBITDA is expected to convert to free cash flow.
Capital Deployment: While 2026 guidance assumes no acquisitions, the company plans to remain disciplined and strategic in capital deployment, actively seeking business development deals in new and existing markets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you speak to tech investments, including AI and advancements for physicians?
A:The company is uniquely positioned with a data-rich environment due to its medical group structure and access to patient data. They are investing in AI across five broad buckets: corporate functions, physician practice workflows (fee-for-service, value-based, patient engagement), revenue cycle innovations, care delivery, and ROI/margin improvement. They are working with partners like Google Cloud, Salesforce, and Athenahealth, and have invested in Navina for clinical decision support. They aim to enhance productivity and margins, targeting a 30%-35% EBITDA margin long-term.
Q:Can you provide some color on practice collection trends for Q4 and 2026 guidance?
A:Practice collections showed variability due to prior period true-ups in Q3 and changes in capitated revenue. The company is prudent in its guidance and does not expect certain revenue increases to carry forward. Care margin is growing consistently at low double digits. Care center locations declined slightly, but provider growth and implemented providers remain strong.
Q:What are your thoughts on utilization trends and changes around ACA and Medicaid enrollment?
A:Ambulatory utilization remains elevated post-COVID, which is positive as it is the lowest cost setting. The company expects churn due to ACA and Medicaid changes but is well-positioned with a diversified model across commercial, MA, MSSP, Medicaid, and exchange populations. They do not see trends abating for their business.
Q:Can you help bridge between historical expectations, 2025 outperformance, and FY '26 guidance on EBITDA to free cash flow conversion?
A:The company has averaged over 100% free cash flow conversion over nine years. They manage a negative float and focus on collections. Cash taxes will begin in 2026, reflected in the 80% conversion guidance. Timing issues at year-end 2025 contributed to outperformance, but they are confident in their 2026 guidance.
Q:What are your updated thoughts on capital deployment with $600 million in cash and no debt?
A:The company prioritizes deploying capital to compound the business, including entering new states, adding providers, and acquiring assets. They maintain a rainy-day fund and avoid leverage. Returning capital to shareholders is a last resort if the stock price deviates from intrinsic value.
Q:What is your perspective on the Evolent acquisition and its synergies?
A:The Evolent acquisition is accretive and allows the company to reach more providers not on their technology stack. They aim to increase savings rates over time and cross-sell into their full medical group business model. Synergies will materialize over the next few years.
Q:How do you plan to increase Evolent ACO savings rates and what is the contribution to 2026 guidance?
A:The company plans to implement their playbook, focusing on quality metrics, patient engagement, and cost management. Savings rate improvements will take time. The acquisition is accretive and contributes to 2026 EBITDA guidance, but specific numbers are not disclosed.
Q:Was there anything driving the sharp drop in corporate G&A expense in the quarter?
A:The decrease was due to lower legal and consulting expenses. The company expects to continue gaining leverage in G&A but advises looking at 2026 guidance for a better view of expenses.
Q:Can you expand on sales momentum in Arizona and other noteworthy markets?
A:The company follows a consistent playbook, starting with an anchor group and building dense delivery systems. Arizona shows strong sales momentum with good population growth and payer dynamics. The approach is similar across markets, with some nuances.
Q:What are your thoughts on the MA contracting environment and its impact on your business?
A:The company believes in shared risk models and has navigated the MA environment carefully. They see opportunities to take on more risk if compensated appropriately. The payer environment is expected to stabilize over time, positioning the company well.
Q:What is the guidance for shared savings in 2026 and updates on newer markets?
A:The company accrues prudently for shared savings and does not expect a material step-up in 2026. Newer markets are progressing as planned, with a portfolio approach to growth.
Q:What are your thoughts on the ACO LEAD model and maintaining performance consistency across cohorts?
A:The company is evaluating the ACO LEAD model and will decide based on patient population and state dynamics. They focus on core competencies like risk management and care delivery to maintain performance consistency across cohorts.
Q:What are the specific AI tools rolled out and future clinical categories for AI improvement?
A:The company is working with partners like Navina and piloting new innovations. AI applications include patient engagement, clinical decision support, and revenue cycle improvements. Future focus areas include care transitions and end-of-life care planning.
Q:What are your thoughts on the value-based care M&A landscape and its impact on your strategy?
A:The company is disciplined in evaluating M&A opportunities, focusing on quality assets. They aim to consolidate the space while maintaining a diversified model. Recent M&A activity in South Florida and California does not directly impact their strategy.
Q:How do you plan to achieve long-term 20% EBITDA growth?
A:The company focuses on entering new states, adding providers, growing value-based lives, M&A, and cost structure improvements. Growth components vary yearly, but the overall direction is upward.
Q:Have conversations with providers shifted due to competitors adopting similar risk models?
A:The company believes its track record and full-service offering differentiate it from competitors. They focus on shared risk models and delivering value to payers and physicians.
Q:What is the growth trajectory for larger deals like IMS in new states?
A:The company takes a long-term view, building dense networks over five years. Growth starts with an anchor group and expands through sales and performance.
Q:How does the challenging payer landscape impact your return on invested capital philosophy?
A:The company evaluates each deal on its merits, balancing investments in new and existing markets. They take a long-term view, focusing on building dense networks and maintaining a diversified approach.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for the Evolent ACO acquisition's EBITDA and revenue contribution, stating that their revenue recognition methodology differs from Evolent's disclosures. They also did not disclose specific shared savings guidance for 2026, emphasizing a prudent approach to accruals.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACO end
ACO entry
ACO value
Arizona anchor
Columbia Evolent
Evolent Health
GA margin
Health ACO
Health market
IMS platform
Implemented Provider
NPS footprint
ability cash
acquisition Evolent
addition Evolent
aim outcome
anchor partner
attribution contribution
balance cash
book scale
combination Implemented
contract enhancement
development result
end sale
environment footprint
environment mission
experience provider
flow health
flow momentum
flow position
footprint presence
footprint value
generation cash
increase value
lady gentleman
leverage platform
life combination
market addition
market health
mission aim
momentum state
outcome experience
partner IMS
platform end
value life
PRVA Transcript
Privia Health Group, Inc. (PRVA) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reveals strong financial metrics, optimistic guidance, and strategic acquisitions, like the Evolent ACO, likely to enhance future profitability. The company’s strategy to deploy capital for growth, coupled with raised guidance, indicates positive market sentiment. Despite some management evasiveness on specifics, the overall tone is confident, suggesting a stock price increase. Given the market cap of $2 billion, the reaction is expected to be moderately positive.
Privia Health Group, Inc. (PRVA) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights strong financial performance, optimistic guidance for 2025, and strategic growth in new markets. The Q&A section revealed positive analyst sentiment, with questions focusing on growth opportunities and market expansion. Despite some cautious language from management, the overall tone was positive. The company's strategic plan and guidance raise are expected to positively impact the stock price, especially given the small-cap nature of the company. The positive sentiment and strategic growth initiatives outweigh any concerns about cautious language or limited Q4 profitability growth.
Privia Health Group, Inc. (PRVA) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call summary and Q&A highlight strong financial performance, strategic growth, and optimistic guidance. Key positive factors include broad-based growth, effective risk management, and favorable regulatory impacts. The IMS integration is progressing well, and the company is raising its 2025 revenue outlook. Despite increased G&A expenses, the company's balanced model and platform enhancements provide significant opportunities. The market cap indicates a moderate reaction, leading to a 'Positive' prediction for stock price movement in the next two weeks.
Earnings call transcript: Privia Health beats Q1 2025 expectations
Positive5-8
The earnings call reveals strong financial performance with a 12.8% increase in total practice collections and a 35.1% rise in adjusted EBITDA. The Arizona acquisition is expected to be EBITDA positive, and the 2025 guidance has been raised. Despite challenges in the Medicare Advantage market and competitive pressures, the company shows solid growth and financial health. The Q&A section highlights management's confidence in future utilization trends and organic growth. Given the company's market cap, the stock price is likely to react positively, potentially in the 2% to 8% range.
PRVA Slides
PRVA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
